Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Tirzepatide
Tirzepatide Dose 1 · 1 trial · 8 indications
HbA1c is the glycosylated fraction of hemoglobin A. HbA1c is measured primarily to identify average plasma glucose concentration over prolonged periods of time. Least Squares (LS) mean was determined by ANCOVA model for endpoint measures: Variable = Baseline + Baseline Antihyperglycemic medication + Baseline Age group + Treatment (Type III sum of squares)
| Arm | Type | Description |
|---|---|---|
| Tirzepatide Dose 1 | EXPERIMENTAL | Double-Blind: Participants receive Tirzepatide by weekly subcutaneous (SC) injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 1 is reached. Open-Label: Participants will continue to receive Tirzepatide at the last dose level |
| Tirzepatide Dose 2 | EXPERIMENTAL | Double-Blind: Participants receive Tirzepatide by weekly SC injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 2 is reached. Open-Label: Participants will continue to receive Tirzepatide at the last dose level |
| Placebo | PLACEBO_COMPARATOR | Double-Blind: Participants receive placebo during the 30-week double-blind period. Open-Label: Participants will switch to Tirzepatide by weekly SC injection starting with a low dose then increase to a higher dose every four weeks until maintenance dose level 1 is reached. |
| Name | Type | Description |
|---|---|---|
| Tirzepatide Dose 1 | DRUG | Administered SC |
| Tirzepatide Dose 2 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Male or female, aged 10 to below 18 years at screening visit * Have type 2 diabetes, treated with diet and exercise and metformin and/or basal insulin. Metformin and/or basal insulin dose must be stable for at least 90 days prior to study screening. * Have HbA1c \>6.5% to ≤11%...
Tirzepatide is being studied for use in obesity, overweight, obstructive sleep apnea, type 1 diabetes, hepatic insufficiency, and renal insufficiency. It is also being investigated in a master protocol for metabolic dysfunction-associated steatotic liver disease. The drug is currently in Phase 2 development for these conditions.
Tirzepatide is a peptide-based small molecule. It is being developed by Eli Lilly and Company for metabolic and weight-related conditions. The drug is in clinical trials for obesity, overweight, and other indications, with ongoing studies in adults and adolescents.
Eli Lilly and Company (NYSE: LLY) is developing Tirzepatide. The company is conducting clinical trials of the drug across multiple indications, including obesity, overweight, and metabolic dysfunction-associated steatotic liver disease. Tirzepatide is currently in Phase 2 development.
Tirzepatide is in Phase 2 development. While some of its clinical trials are in Phase 3, the overall development stage for the drug is listed as Phase 2. It is an investigational drug and has not been approved by regulatory authorities.
Tirzepatide is being studied in several trials, including NCT05556512, a Phase 3 study on morbidity and mortality in adults with obesity, and NCT06075667, a Phase 3 study in adolescents with obesity or overweight. It is also part of NCT07165028, a master protocol in metabolic dysfunction-associated steatotic liver disease.
Yes, Tirzepatide is also known as LY3298176. Clinical trials such as NCT03482024, a study in participants with impaired kidney function, use the LY3298176 name for the drug. Both names refer to the same investigational compound developed by Eli Lilly.